See how top analysts and institutions rate ADBE — including buy, hold, and sell recommendations.
| Rating Source | Action | Rating | Target Price | Updated |
|---|---|---|---|---|
| Morgan Stanley | Downgrade | Overweight → Equal-Weight | $450 | 2025-09-24 |
| BMO Capital Markets | Reiterated | Outperform | $450 → $405 | 2025-09-12 |
| Melius | Downgrade | Hold → Sell | $310 | 2025-08-11 |
| Rothschild & Co Redburn | Downgrade | Neutral → Sell | $280 | 2025-07-02 |
| Date | Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|---|
| November 2025 | 5 | 20 | 12 | 3 | 0 |
| October 2025 | 5 | 20 | 12 | 3 | 0 |
| September 2025 | 5 | 20 | 12 | 3 | 0 |
| August 2025 | 6 | 19 | 12 | 2 | 0 |
The majority of institutional investors have issued a "Buy" rating for ADBE, and analyst sentiment aligns closely, with very few "Sell" recommendations. This suggests a broadly favorable outlook for the stock's performance.
